Author:
Chen Lei,Brown Jacqueline,Marmaduke Dale Quentin,Mayo Carlos,Grau Gerrit,Lau Yiu-Keung,Obasaju Coleman K
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA, MASCC Skin Toxicity Study Group (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079–1095.
https://doi.org/10.1007/s00520-011-1197-6
2. Kloth DD, Iacovelli L, Arbuckle R, McIntosh AC (2010) The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist. P T 35(4):219–229
3. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):15–31.
https://doi.org/10.1517/14728222.2011.648617
4. Hirsh V (2011) Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol 18(3):126–138
5. Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6(10):803–812.
https://doi.org/10.1038/nrc1970
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献